Intellia Therapeutics (NTLA) Tax Provisions (2015)

Intellia Therapeutics' (NTLA) quarterly Tax Provisions came in at -$246000.0 in Q4 2015, up 12.77% on a QoQ basis from -$282000.0 in Q3 2015.

Intellia Therapeutics (NTLA) Tax Provisions (2015) Analysis & Trends

Intellia Therapeutics (NTLA) has 1 years of Tax Provisions data on file, last reported at -$246000.0 in Q4 2015.

On a quarterly basis, Tax Provisions changed N/A year-over-year to -$246000.0 in Q4 2015; TTM through Sep 2016 was -$246000.0, a N/A change from a year earlier, with the FY2015 full-year figure at -$1.0 million, changed N/A from the prior year.
Tax Provisions for Q4 2015 stood at -$246000.0, up from -$282000.0 in the prior quarter.
Over the last five years, Tax Provisions for NTLA reached as high as -$102000.0 in Q1 2015 and fell as low as -$382000.0 in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	125,146.46
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	31.86 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-60.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Intellia Therapeutics	1.27 Bn	1.27 Bn	-	-

Download Data